ReNeuron Group plc ReNeuron signs exosome collaboration (1717M)
January 04 2019 - 2:00AM
UK Regulatory
TIDMRENE
RNS Number : 1717M
ReNeuron Group plc
04 January 2019
AIM: RENE 4 January 2019
ReNeuron Group plc
("ReNeuron" or the "Company")
ReNeuron signs exosome collaboration
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, today announces that it has
signed a collaboration agreement with a US-based biopharmaceutical
company to explore the use of the Company's exosome technology
platform as a potential delivery vehicle for synthetic
oligonucleotides used in gene therapy.
In the collaboration, ReNeuron will use its proprietary exosomes
as well as sequence-based know-how and the US-based
biopharmaceutical company will provide its expertise in the field
of synthetic oligonucleotides to optimise their loading into
exosomes.
If the initial feasibility stage of the collaboration is
successful, candidates with suitable pharmaceutical properties will
be taken into the next part of the collaboration which will
evaluate pre-clinical safety and potential efficacy.
During the initial feasibility stage there are no cash payments
between the parties. On successful completion of the feasibility
stage, it is anticipated that a product cross-licensing agreement
will be signed by the parties ahead of the pre-clinical and
clinical development of the therapeutic candidates.
Commenting on the agreement, Olav Hellebø, Chief Executive
Officer of ReNeuron, said:
"Exosomes are biological nanoparticles ideally suited to the
delivery of nucleic acid-based therapeutics due to their natural
occurrence and abundance, their ability to protect their cargo from
degradation and their potential for favourable bio-distribution. We
are delighted to be collaborating with a biopharmaceutical company
that has considerable experience in the development of novel
oligonucleotide-based therapeutics."
ENDS
Enquiries: ReNeuron +44 (0) 20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited (NOMAD and
Joint Broker)
Jonathan Senior, Stewart Wallace, Ben Maddison +44 (0) 20 7710 7600
N+1 Singer Advisory LLP (Joint Broker)
Mark Taylor +44 (0) 20 7496 3000
About ReNeuron's Exosome Platform
ReNeuron has established an endogenous, high-yielding, CTX
cell-line derived exosome platform that can be produced through a
fully qualified, xeno-free, optimised scalable GMP process.
Conditional immortalisation of the cell-line ensures consistent
exosome product. The company has been able to successfully load
miRNA and proteins into its exosomes.
The CTX producer cell-line can also be modified to carry
siRNA/mRNA/miRNA, CRISPR/Cas9, proteins and small-molecule
inhibitors and can be engineered to target particular tissues.
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that would
otherwise be unable to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This announcement contains forward-looking statements with
respect to the financial condition, results of operations and
business achievements/performance of ReNeuron and certain of the
plans and objectives of management of ReNeuron with respect
thereto. These statements may generally, but not always, be
identified by the use of words such as "should", "expects",
"estimates", "believes" or similar expressions. This announcement
also contains forward-looking statements attributed to certain
third parties relating to their estimates regarding the growth of
markets and demand for products. By their nature, forward-looking
statements involve risk and uncertainty because they reflect
ReNeuron's current expectations and assumptions as to future events
and circumstances that may not prove accurate. A number of factors
could cause ReNeuron's actual financial condition, results of
operations and business achievements/performance to differ
materially from the estimates made or implied in such
forward-looking statements and, accordingly, reliance should not be
placed on such statements.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRDXLFBKFFXBBX
(END) Dow Jones Newswires
January 04, 2019 02:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2023 to Apr 2024